Prospective superficial EPR in-vivo dosimetry study during hypofractionated radiotherapy of breast cancer patients treated with helical tomotherapy.

Sebastian HöfelMatteo GandaliniMichael K FixMalte DrescherFelix Zwicker

Published in: Radiation oncology (London, England) (2021)

Superficial EPR IVD is suitable as additional safeguard for dose delivery during helical tomotherapy of breast cancer. Despite positional uncertainties in clinical routine, the observed dose deviations at the ipsilateral breast were on average small compared to national reporting thresholds for total dose deviations (i.e. 10%/4 Gy). EPR IVD may allow for the detection of critical dose errors during whole breast irradiations.

Keyphrases

radiation therapy
early stage
adverse drug
small cell lung cancer
patient safety
clinical practice
electronic health record
loop mediated isothermal amplification